Pegylated interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B
Antimicrobial Agents and Chemotherapy, cilt.51, sa.8, ss.3020-3022, 2007 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 51 Sayı: 8
- Basım Tarihi: 2007
- Doi Numarası: 10.1128/aac.00088-07
- Dergi Adı: Antimicrobial Agents and Chemotherapy
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.3020-3022
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Forty-eight hepatitis B virus (HBV) E antigen-negative chronic hepatitis B patients received pegylated interferon alfa-2b either alone or with lamivudine for 48 weeks and were followed for an additional 24 weeks. At the end of follow-up, virological response rates (HBV DNA levels of <400 copies/ml) were similar in the monotherapy (24%) and combination therapy (26%) groups. Copyright © 2007, American Society for Microbiology. All Rights Reserved.